Black Rock Inc. Genprex, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.37 - $1.04 $249 - $699	-673 Reduced 0.15%	455,688 $182,000
Q2 2023 Aug 11, 2023	SELL	$0.74 - $1.1 $82,790 - $123,066	-111,879 Reduced 19.69%	456,361 $433,000
Q1 2023 May 12, 2023	BUY	$0.76 - $1.78 $2,745 - $6,429	3,612 Added 0.64%	568,240 $517,000
Q4 2022 Feb 13, 2023	BUY	$1.0 - $58.8 $1,640 - $96,432	1,640 Added 0.29%	564,628 $818,000
Q3 2022 Nov 14, 2022	SELL	$1.32 - $58.0 $19,536 - $858,400	-14,800 Reduced 2.56%	562,988 $795,000
Q2 2022 Aug 12, 2022	SELL	$1.28 - $2.31 $5,242 - $9,461	-4,096 Reduced 0.7%	577,788 $803,000
Q1 2022 May 12, 2022	BUY	$1.82 - $3.5 $5,472 - $10,524	3,007 Added 0.52%	581,884 $1.32 Million
Q4 2021 Feb 10, 2022	BUY	$1.21 - $2.7 $47,592 - $106,199	39,333 Added 7.29%	578,877 $758,000
Q3 2021 Nov 09, 2021	SELL	$2.59 - $3.36 $23,364 - $30,310	-9,021 Reduced 1.64%	539,544 $1.45 Million
Q2 2021 Aug 11, 2021	BUY	$3.11 - $4.87 $1.71 Million - $2.67 Million	548,565 New	548,565 $1.84 Million

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.